ESTRADIOL AND NORGESTIMATE Drug Patent Profile
✉ Email this page to a colleague
When do Estradiol And Norgestimate patents expire, and when can generic versions of Estradiol And Norgestimate launch?
Estradiol And Norgestimate is a drug marketed by Barr and is included in one NDA.
The generic ingredient in ESTRADIOL AND NORGESTIMATE is estradiol; norgestimate. There are seventy-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estradiol; norgestimate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Estradiol And Norgestimate
A generic version of ESTRADIOL AND NORGESTIMATE was approved as estradiol; norgestimate by BARR on April 29th, 2005.
Summary for ESTRADIOL AND NORGESTIMATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Clinical Trials: | 29 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ESTRADIOL AND NORGESTIMATE at DailyMed |
Recent Clinical Trials for ESTRADIOL AND NORGESTIMATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Benha University | Phase 2/Phase 3 |
| Amgen | Phase 1 |
| Gilead Sciences | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for ESTRADIOL AND NORGESTIMATE
US Patents and Regulatory Information for ESTRADIOL AND NORGESTIMATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | ESTRADIOL AND NORGESTIMATE | estradiol; norgestimate | TABLET;ORAL | 076812-001 | Apr 29, 2005 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
